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Abstract
Purpose—This study investigated the effects of the physicochemical properties of antibiotics on 
the morphology, loading efficiency, size, release kinetics, and antibiotic efficacy of loaded 
poly(DL-lactic-co-glycolic acid) (PLGA) microparticles (MPs) at different loading percentages.
Methods—Cefazolin, ciprofloxacin, clindamycin, colistin, doxycycline, and vancomycin were 
loaded at 10 and 20 weight percent into PLGA MPs using a water-in-oil-in water double emulsion 
fabrication protocol. Microparticle morphology, size, loading efficiency, release kinetics, and 
antibiotic efficacy were assessed.
Results—The results from this study demonstrate that the chemical nature of loaded antibiotics, 
especially charge and molecular weight, influence the incorporation into and release of antibiotics 
from PLGA MPs. Drugs with molecular weights less than 600 Da displayed biphasic release while 
those with molecular weights greater than 1000 Da displayed triphasic release kinetics. Large 
molecular weight drugs also had a longer delay before release than smaller molecular weight 
drugs. The negatively charged antibiotic cefazolin had lower loading efficiency than positively 
charged antibiotics. Microparticle size appeared to be mainly controlled by fabrication parameters, 
and partition and solubility coefficients did not appear to have an obvious effect on loading 
efficiency or release. Released antibiotics maintained their efficacy against susceptible strains over 
the duration of release. Duration of release varied between 17–49 days based on the type of 
antibiotic loaded.
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Conclusions—The data from this study indicate that the chemical nature of antibiotics affects 
properties of antibiotic-loaded PLGA MPs and allows for general prediction of loading and release 
kinetics.
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1.0 Introduction
Infection remains a major complication of bone injury due to pathology or traumatic injury. 
The presence of infection is a serious deterrent to healing in bone tissue and may result in 
adverse outcomes including non-union and amputation [1]. The current standard of care 
relies on irrigation and debridement of infected tissue in combination with either systemic 
antibiotics over the course of several weeks to months or local delivery of antibiotic from 
poly(methylmethacrylate) (PMMA) beads, both of which have their disadvantages [2,3]. 
Systemic antibiotics come with a variety of undesirable side effects, including 
nephrotoxicity and ototoxicity, that can prove challenging when attempting to achieve 
sufficient concentration of antibiotic in the infected area to treat the infection. In addition, 
many antibiotics are only administered intravenously, and the cost of both inpatient and 
outpatient care is considerable [4]. Implantation of antibiotic-loaded PMMA beads achieves 
local delivery of antibiotics, but the majority of drug is released in the first few days, and the 
implantation of a foreign body in an infected area can cause further infectious complications 
via bacterial attachment to the biomaterial surface [3,5–9]. Additionally, the presence of 
sub-therapeutic levels of antibiotic through inadequate systemic or local delivery can 
contribute to the development of antibiotic resistance, which is a significant problem for 
both the patient and the public [1,7].
Poly(DL-lactic-co-glycoic acid) (PLGA) microparticles (MPs) have been used as a delivery 
vehicle for antibiotics of almost all types due to its tunable degradation profile and 
biocompatible degradation products [2,3,10]. Several studies have reported the release of 
antibiotics from PLGA MPs to occur over the span of weeks to months [4,11–14]. 
Antibiotic-loaded PLGA MPs have also been incorporated into tissue engineering scaffolds 
for the purpose of mitigating infection, and release has been reported to occur over 8 weeks 
in vitro and efficacy of the construct has been established in an infected in vivo model [3,5–
9,11,15].
Bone infections are caused by of a variety of bacteria, most commonly Staphylococcus 
aureus, but also including coagulase-negative Staphyloccus spp., Streptococcus spp., E. coli, 
and Pseudomonas aeruginosa [16,17]. Because not all antibiotics are effective against all 
bacteria, antibiotic therapy must be carefully considered in order to avoid undertreating the 
infection or promoting antibiotic resistance. For this reason, many different classes and 
types of antibiotics must be able to be incorporated into PLGA MPs. As previous studies 
have shown, there are a multitude of fabrication parameters for PLGA MPs that affect drug 
loading and rate of release [18,19]. Additionally, the type of antibiotic may also play a role 
in the final characteristics of the loaded MPs due to polymer/drug interactions. The ability to 
use knowledge of the chemical nature of antibiotics to predict and manipulate the properties 
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and release kinetics of PLGA MPs is advantageous for designing fabrication protocols that 
minimize antibiotic loss while ensuring a favorable antibiotic release profile for treating 
bone infections.
This study investigated six antibiotics of different classes and chemistries into PLGA MPs 
and evaluated the effects of the physicochemical properties of each antibiotic on the 
properties and release kinetics of antibiotic-loaded PLGA MPs. A single protocol was used 
to fabricate all MPs in order to isolate the effects of the drug on MP properties. It was 
hypothesized that charge, molecular weight, and partition and solubility coefficients of the 
incorporated antibiotic would influence the loading efficiency, size, and release kinetics of 
the resulting MPs, and that the antibiotic activity of the released drug would be maintained.
2.0 Materials and Methods
2.1 Materials
Poly(DL-lactic-co-glycolic acid) was obtained from Lakeshore Biomaterials (Birmingham, 
AL) and had a copolymer ratio of 50:50, a weight average molecular weight of 36 kDa, and 
a number average molecular weight of 21 kDa. Poly(vinyl) alcohol (PVA), Mueller-Hinton 
broth, ciprofloxacin, colistin sulfate, doxycycline hyclate, and vancomycin hydrochloride 
were obtained from Sigma Aldrich (St Louis, MO). Cefazolin sodium and clindamycin 
hydrochloride were obtained from Fisher Scientific (Waltham, MA). Properties of these 
antibiotics are detailed in Table 1. Colistin (polymyxin E) has two HPLC retention times due 
to this drug being a mixture of two drugs, colistin A and colistin B (Table 1). Experimental 
values for logP and logS were used when available, otherwise predicted values were 
calculated using ALOGPS (VCCLabs) [20,21]. The charge of antibiotics at pH 6.4–7.4 is 
shown, which encompasses the pH of aqueous phases during fabrication and the pH of the 
release medium. Ciprofloxacin was acidified with 5N HCl in order to create the water-
soluble hydrochloride salt of ciprofloxacin. Bacterial strains Staphylococcus aureus (ATCC 
29213), Escherichia coli (ATCC 25922), and Pseudomonas aeruginosa (ATCC 27853) 
were obtained from ATCC (Manassas, VA).
2.2 Microparticle Fabrication
PLGA MPs containing various antibiotics were fabricated using a water-in-oil-in-water 
double emulsion solvent evaporation technique [11]. The internal water phase consisted of 
antibiotics dissolved in 0.3 wt% PVA in water at 10 wt% or 20 wt% of final microparticle 
weight, or a concentration of either 139 mg/mL or 312.5 mg/mL, respectively. All 
antibiotics were fully solubilized in the internal aqueous phase after 30 min on a rotary 
shaker table at 37°C. The oil phase consisted of PLGA dissolved in methylene chloride at a 
concentration of 222 mg/mL. The internal phase was added to the oil phase at a ratio of 
1:5.6 v/v and emulsified using a Qsonica Q125 probe sonicator (Newtown, CT). The 
internal phase/oil phase emulsion was poured into a beaker containing 250 mL of outer 
phase comprising 0.3 wt% PVA and 4 wt% NaCl stirring at 700 rpm. The solvent was 
allowed to evaporate over 4 hrs, and the resulting microparticles were washed, frozen, and 
lyophilized. Microparticles were sieved to less than 300 μm and stored at −20°C. Blank 
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microparticles were fabricated using an internal phase of 0.3 wt% PVA without antibiotic. 
Each formulation was synthesized in triplicate.
2.3 Scanning Electron Microscopy
SEM was used to examine the external and internal morphology of blank and antibiotic-
loaded PLGA MPs. The internal morphology of the MPs was exposed by embedding them 
in HistoPrep, freezing, and creating 10 μm sections with a Leica cryotome (Allentown, NJ). 
The microparticles were sputter-coated with 20 nm of gold using a Torr International 
CrC-150 sputtering system (New Windsor, NY) and observed under a FEI Quanta 400 field 
emission scanning electron microscope (Hillsboro, OR) at an accelerating voltage of 5 kV.
2.4 Determination of Loading Efficiency
The loading efficiency of antibiotics into PLGA MPs was determined by dissolving MPs in 
methylene chloride and extracting the antibiotic into either phosphate-buffered saline (PBS) 
(pH 7.4) for cefazolin, ciprofloxacin, clindamycin, and doxycycline or potassium phosphate 
monobasic (pH 2.85) for colistin and vancomycin. Briefly, 20 mg of microparticles were 
dissolved in 2 mL of methylene chloride for 30 minutes. 20 mL of PBS (pH 7.4) was added 
and the mixture was stirred rapidly for 2 hrs to allow extraction of antibiotic into the PBS 
and evaporation of the organic solvent. Vancomycin and colistin could not be extracted with 
this method, so the protocol was modified. As before, 20 mg of MPs were dissolved in 2 mL 
methylene chloride for 30 min. To extract vancomycin and colistin, 20 mL of potassium 
phosphate monobasic was added, sonicated for 5 min, then stirred rapidly for 2 hrs. The 
concentration of antibiotic in the aqueous phase was determined by HPLC. Loading 
efficiency was calculated as
where Dout is the amount of drug recovered from Pout, a specified amount of microparticles 
and Din and Pin are the amounts of antibiotic and polymer used in the initial fabrication of 
the MPs, respectively.
2.5 Microparticle Size Determination
Microparticle size was determined using a Beckman Coulter Counter (Brea, CA). Briefly, 20 
mg of MPs were mixed into Isotone II solution, and a 280 μm aperture was used to 
determine average particle diameter ± standard deviation. Microparticle diameter data was 
collected using n = 1000 particles per MP batch (n=3 per formulation). Each batch of MPs 
was tested in triplicate.
2.6 Antibiotic Release from PLGA Microparticles
Release kinetics of each of the antibiotics from PLGA MPs was determined by placing 50 
mg of MPs into 5 mL of PBS (pH 7.4) under mild shaking (n=3). Each replicate was 
synthesized independently in order to assess inter-batch reliability. The supernatant was 
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completely removed and replaced with fresh PBS at 12 hours and days 1, 4, 7, and biweekly 
until 49 days. The release medium was filtered with a 0.2 μm syringe filter, and the 
concentration of antibiotic was determined by HPLC. The HPLC system comprised a 
Waters 2695 separation module and 2996 photodiode array detector (Milford, MA) with a 
Waters XTerra RP 18 column (250mm × 4.6mm) at 35 °C. For cefazol in, ciprofloxacin, 
clindamycin, doxycycline, and vancomycin, the elution was performed with a flow rate of 1 
mL/min in a mobile phase consisting of 25 mM KH2PO4 (Sigma, HPLC grade, pH 3) and 
acetonitrile (Sigma, HPLC grade). Peaks were eluted with a linear gradient of 5%–60% 
acetonitrile in water over 20 min. For colistin, the elution was performed with a flow rate of 
0.5 mL/min in a mobile phase consisting of acetonitrile (HPLC grade) and water (0.22 μm 
filtered with 0.1 vol.% trifluoroacetic acid). Peaks were eluted with a linear gradient of 
10%–65% acetonitrile in water over 20 min. Absorbance was monitored at λ = 270, 274, 
204, 214, 350, and 274 nm for cefazolin, ciprofloxacin, clindamycin, colistin, doxycycline, 
and vancomycin, respectively. Standard solutions with antibiotic in PBS buffer (pH 7.4) 
were tested in the range of 5–1000 μg/mL. The percent cumulative release was calculated as 
amount of antibiotic released at each timepoint as a percentage of total antibiotic loaded. 
Release curves were divided into phases based on a line of best fit analysis.
2.7 Susceptibility Testing
The minimum inhibitory concentration (MIC) of released antibiotics against relevant strains 
of bacteria was tested using a broth microdilution assay as described in ISO standard 20776. 
Briefly, supernatant from the release study was sterile filtered and used as a stock solution in 
the broth microdilution assay. The stock solution was serially diluted with sterile Mueller-
Hinton broth to 50 μL aliquots with concentrations ranging from 0 mg/L to 16 mg/L. Early 
and late timepoints were tested and were determined by using the earliest and latest 
timepoints at which there was at least 32 μg/mL of antibiotic in solution. Cefazolin was 
tested at days 7 and 17, ciprofloxacin at 0.5 and 14, clindamycin at 7 and 17, colistin at 14 
and 31, doxycycline at 10 and 17, and vancomycin at 14 and 35. A 0.5 MacFarland standard 
of bacteria cultured in Mueller-Hinton broth was diluted 1:100 in sterile Mueller-Hinton 
broth, and 50 μL of the inoculum was added to each well. The lowest concentration well 
without growth after 18 h of culture at 37°C was denoted the MIC.
2.8 Statistical Analysis
All values are reported as mean ± standard deviation. Loading efficiency, MP size, release 
phases and cumulative release were compared using ANOVA with post-hoc analysis by 
Tukey’s honestly significant difference with an a priori level of significance set at α=0.05 (n 
= 3 samples). The MICs of each antibiotic were compared using Kruskal-Wallis with post-
hoc analysis by Mann-Whitney U-test (n = 3). JMP (Version 7, SAS Institute Inc., Cary, 
NC) was used for ANOVA and post-hoc testing. R (R Development Core Team, 2010) was 
used for univariate and multivariate linear regression modeling [22].
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3.0 Results
3.1 Scanning Electron Microscopy
Representative SEM images of 10 wt% loaded and 20 wt% loaded MPs, both whole and 
sectioned, are shown in Fig. 1. The exterior morphology of the MPs is smooth, with few to 
no macropores noted. The MPs appear to have porous interiors surrounded by a thin shell of 
relatively non-porous PLGA, with the exception of 20 wt% ciprofloxacin, which appears to 
be uniformly porous throughout.
3.2 Loading efficiency
Loading efficiencies for the various formulations of antibiotic-loaded PLGA MPs can be 
seen in Table 2. Ciprofloxacin loaded MPs show a decrease in loading efficiency when 
loading is increased from 10 wt% to 20 wt% due to precipitation of the antibiotic out of the 
primary water-in-oil emulsification during loading (p<0.05). While ciprofloxacin could be 
dissolved at 312.5 mg/mL in the internal aqueous phase, the solution was unstable and 
precipitated immediately upon addition of the polymer/dichloromethane solution. All other 
antibiotics show no significant difference in loading efficiency between 10 wt% and 20 wt% 
(p>0.05). At 10 wt% loading, the loading efficiency of cefazolin is significantly less than all 
other antibiotics. At 20 wt% loading, cefazolin and ciprofloxacin have decreased loading 
efficiencies compared to all other antibiotics.
3.3 Microparticle Size
Microparticle size for each formulation can be seen in Table 3. In the 10 wt% loaded groups, 
ciprofloxacin MPs are larger than vancomycin MPs (p<0.05). In the 20 wt% loaded group, 
there is no difference in average MP size between any of the antibiotics (p>0.05). There is 
no difference in MP size for any other antibiotic between 10 wt% loaded and 20 wt% loaded 
MPs, and there is no difference between any formulation and blank MPs (p>0.05). The 
reported distribution is based on number of particles.
3.4 Antibiotic Release
Release curves for each formulation of MP are shown in Fig. 2. The amount of antibiotic 
released at each time point was well below the solubility of each drug, indicating that the 
release kinetics seen are not a result of saturation of the medium. The release curves for each 
formulation were analyzed by comparing the rate of release during different phases of 
release. Rates of release are shown in Supplemental Tables SI and SII. Cefazolin, 
ciprofloxacin, clindamycin, and doxycycline shared a sigmoidal release curve with biphasic 
release while vancomycin and colistin appeared to share similar triphasic release kinetics.
Of note, during Phase 1, 20 wt% ciprofloxacin loaded MPs have a significantly greater burst 
release than 20 wt% cefazolin, clindamycin, or doxycycline loaded MPs (p<0.05); there was 
no difference between 20 wt% cefazolin, clindamycin, or doxycycline loaded MPs (p>0.05). 
During Phase 2, the phase in which the majority of antibiotic is released, there is no 
difference in release rate between cefazolin, ciprofloxacin, clindamycin, and doxycycline 
when comparing either 10 wt% to 20 wt% loaded MPs or when comparing between 
cefazolin, ciprofloxacin, clindamycin, and doxycycline (p>0.05).
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No significant differences between 10 wt% and 20 wt% loaded colistin and vancomycin 
loaded MPs were noted in Phase 1 or 2 (p>0.05). During Phase 2, 20 wt% loaded colistin 
MPs released more quickly than 10 wt% loaded colistin MPs (p<0.05). During Phase 3, the 
major release phase for colistin and vancomycin, there was no differences in release rates 
between colistin and vancomycin loaded MPs (p<0.05).
Cumulative percent release was not statistically different between the 10 wt% and 20 wt% 
loaded MPs for any antibiotic (p>0.05). In the 10 wt% loaded group, there was no difference 
in cumulative percent release between any antibiotics (p>0.05). In the 20 wt% loaded group, 
doxycycline MPs released less of the incorporated drug than clindamycin MPs (p<0.05).
3.5 Effects of Charge, Molecular Weight, Partition Coefficient, and Solubility Coefficient
The effects of charge, molecular weight, partition coefficient and solubility coefficient on 
loading efficiency, major release phase rate, and length of lag phase can be seen in 
Supplemental Figs. S1, S2, and S3, respectively. The correlation coefficients for the 
univariate linear regression can be found in Table 4. The length of lag phase was determined 
by the first timepoint at which the percent cumulative release increased more than 5%, as 
this increase was a precursor to the beginning of the release phase. The charge of the loaded 
antibiotic is strongly correlated to the loading efficiency in 10 wt% and 20 wt% loaded MPs 
(Table 4). When 20 wt% loaded ciprofloxacin MPs are excluded due to the precipitation of 
antibiotic during fabrication, the correlation coefficient between charge and loading 
efficiency for 20 wt% loaded MPs is 0.87. Correlations of loading efficiency and release rate 
to logP and logS are weak (<0.5) (Table 4). Length of lag phase is strongly correlated to 
logS and very strongly correlated to molecular weight (Table 4). Multivariate linear 
regression modeling showed no relationship between any of the explanatory variables 
(charge, molecular weight, logP, logS) and the response variables (loading efficiency, major 
release rate, length of lag phase).
3.6 Susceptibility
The MIC of both fresh antibiotic and antibiotic released from microparticles against 
standard strains of bacteria at early and late timepoints is shown in Table 5. Fresh antibiotic, 
antibiotic released at an early timepoint, and antibiotic released at a late timepoint have the 
same efficacy against the tested bacterial strain (p>0.05).
4.0 Discussion
Sustained local delivery of antibiotics via a PLGA particulate carrier is an attractive 
approach to the problem of implant-associated infections given the advantages of increased 
local concentrations, decreased systemic toxicity, and increased duration of antimicrobial 
coverage [15,23]. While antibiotic-loaded PLGA MPs have been widely investigated in the 
literature and have transitioned into the clinic on a limited basis, there is a relative dearth of 
studies that investigate the effect of drug characteristics on the properties and release 
kinetics of the resulting MPs.
In this study, six antibiotics of different classes were loaded at 10 wt% and 20 wt% into 
PLGA MPs using a single protocol, and the resulting MPs were assessed for morphology, 
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loading efficiency, size, release kinetics, and activity against susceptible bacterial strains. It 
was hypothesized that the properties and release kinetics of the MPs could be predicted 
using known properties of the antibiotics being loaded such as charge, molecular weight, 
partition coefficient, and solubility coefficient. The results of this study indicate that certain 
antibiotic properties affect the characteristics of antibiotic-loaded PLGA MPs their release 
kinetics and that the chemical nature of antibiotics should be considered when designing 
fabrication protocols to achieve desired outcomes such as high loading efficiency and 
predictable release kinetics.
The external morphology of the MPs by SEM (Fig. 1) is consistent with previous studies 
that demonstrate that high polymer concentration results in decreased surface porosity. This 
occurs via the formation of micropores due to the increased viscosity of the water/oil 
emulsion and stabilization of the film at the oil/water interface [18,24]. The internal 
morphology of the MPs varies between antibiotics. The difference between the large pores 
seen in 20 wt% ciprofloxacin and 10 wt% and 20 wt% clindamycin MPs and the numerous 
small pores seen in ciprofloxacin 10 wt%, cefazolin, colistin, doxycycline, and vancomycin 
MPs may be due to interactions between the internal aqueous phase and the oil phase. While 
all antibiotics within their respective wt% loadings were dissolved at the same concentration 
(either 139 mg/mL or 312.5 mg/mL) in the same volume of internal phase, the aqueous 
antibiotic internal phase may either impart different viscosities to the drug/polymer emulsion 
or influence interfacial properties through interactions with the polymer, the PVA surfactant, 
or the external aqueous phase [25–27]. Mao et al. demonstrated that MPs fabricated with 
high viscosity polymer have small internal pores while MPs fabricated with low viscosity 
polymer have large internal pores, possibly due to the ability of the trapped aqueous internal 
phase to coalesce within a lower viscosity polymer solution [18]. The emulsion of 
clindamycin with PLGA may result in a lower viscosity solution than the emulsion of 
cefazolin, colistin, doxycycline, and vancomycin, resulting in the observed internal pore 
morphologies. Ciprofloxacin 20 wt% is unique in that it is the only formulation in which the 
dissolved drug solution precipitated during fabrication. This could contribute to the 
interesting internal morphology seen, where the large pores are either due to a lower 
viscosity with less ciprofloxacin entrapped or the presence of aggregates of ciprofloxacin 
precipitate.
The loading efficiencies of the MPs fabricated in this study are comparable to or better than 
available previous studies [11–13,28], especially given the relative hydrophilicity of these 
drugs. Only 10 and 20 wt% cefazolin-loaded MPs and 20 wt% ciprofloxacin-loaded MPs 
had entrapment efficiencies less than 70%. These results are likely due to a combination of 
two factors: polymer phase concentration and charge of the loaded antibiotic.
Previous studies have shown that increasing the polymer phase concentration increases the 
entrapment efficiency of loaded drug [18,19,24]. High polymer concentration can increase 
loading efficiency by stabilizing the interface between oil phase and external phase, 
resulting in the formation of particles with a dense polymer matrix, high surface area-to-
volume ratio, and smaller, more tortuous pore networks, leading to decreased water 
penetration and decreased leaching of drug during the hardening phase [18,24]. Since the 
polymer concentration was kept constant for each formulation, charge is likely responsible 
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for the difference between high loading efficiencies formulations and 10 wt% cefazolin, 20 
wt% cefazolin, and 20 wt% ciprofloxacin.
Charge is another parameter than can affect loading efficiency. As seen in Table 4, loading 
efficiency is positively correlated with charge, with correlation coefficients of 0.82 and 0.68 
for 10 wt% and 20 wt% loaded MPs, respectively. When ciprofloxacin 20 wt% is excluded 
due to precipitation of ciprofloxacin out of the emulsification phase, the correlation for 20 
wt% loaded MPs is 0.87 (Table 4). Because the PLGA used in this study is uncapped and 
negatively charged, the low entrapment efficiency seen in the cefazolin groups is likely due 
to the negative charge of cefazolin at pH>3.6 (Table 1) [29–31]. In contrast, all other 
antibiotics are either zwitterionic or positively-charged at the pH of the internal and external 
aqueous phases. Colistin, a polypeptide antibiotic, demonstrated particularly high 
entrapment efficiency in both 10 wt% and 20 wt% formulations that could be attributed to 
the strong positive charge at pH 6.4. In the 10 wt% group, colistin loaded more efficiently 
than doxycycline, while in the 20 wt% group, colistin loaded more efficiently than 
vancomycin. Doxycycline, a tetracycline antibiotic, and vancomycin, a glycopeptide 
antibiotic, both had high entrapment efficiencies and are positively charged at pH 6.4, but 
due to the multitude of pKa values spanning a large pH range, both antibiotics also contain a 
negative charge that may have lowered its loading efficiency compared to colistin [32,33]. 
Negative-negative antibiotic-polymer charge interactions can promote the expulsion of 
cefazolin from the MPs, while favorable positive-negative interactions enhance the retention 
of zwitterionic and positively charged antibiotics. However, the presence of negative 
charges still appears to affect entrapment even when the overall charge is positive. These 
results demonstrate that while polymer concentration heavily influences the loading of 
PLGA MPs, the charge of the drug is also an important factor that can affect loading 
efficiency when using a w/o/w technique. Efficient incorporation of drug into the carrier is 
an important design criteria for local delivery systems given the expense of newer antibiotics 
necessary to treat common drug-resistant organisms[34].
Previous studies of PLGA w/o/w fabrication parameters indicate that MP size is largely a 
function of polymer concentration and stirring speed [18,19,24,35]. In this study, fabrication 
parameters, particularly temperature, internal and external phase volumes, and polymer 
concentration, were held constant between formulations, so differences in size may be 
attributed to characteristics of the incorporated drug. The MPs synthesized in this study were 
not statistically different in size compared to blank (unloaded) MPs, owing in part to the 
heterogeneity of MP sizes produced.
The fabrication parameters of antibiotic-loaded PLGA MPs can greatly affect release, and 
many previous studies have investigated the effects of the multitude of parameters that can 
be altered, such as internal phase volume, choice of polymer and polymer phase 
concentration, choice and concentration of surfactant, and drug loading [12,13,18,19,24,36]. 
Previous studies have also investigated the effects of different hydrophobic, minimally water 
soluble drugs on release from PLGA films and have found that the type of drug incorporated 
can affect release kinetics[37–39]. In this study of relatively hydrophilic and freely water 
soluble antibiotics, fabrication parameters were kept constant in order to examine the effects 
of different antibiotics on release kinetics.
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The release of antibiotics from PLGA MPs in this study was characterized by little to no 
burst release during the lag phase, followed by daily release of drug above MIC for 17–49 
days, depending on the type and loading of antibiotic. Similar to a previous study of 
antibiotic release from PLGA MPs from our laboratory, release from MPs in this study 
appears to be controlled by both diffusion and degradation [11]. The data suggest that 
molecular weight and solubility play a role in determining how quickly drug can begin to 
diffuse out from a dense polymer matrix, as suggested by the strong positive correlation 
between molecular weight and length of the lag phase and logS and length of the lag phase 
(Table 4). Solubility does not appear to significantly affect the rate of release during the 
release phases, as indicated by the very weak correlation between the two factors (Table 4). 
Relatively low molecular weight drugs (<600 Da), including cefazolin, ciprofloxacin, 
clindamycin, and doxycycline, displayed a biphasic release profile while larger molecular 
weight drugs (>1100 Da) displayed a triphasic release profile.
Typical release profiles for drug-loaded PLGA MPs demonstrate early off-loading of a large 
percentage of drug. In this study, early drug release from 0–1 days, which normally 
corresponds to diffusion-controlled release, is minimal due to a combination of decreased 
drug adsorption on the surface of the MPs and restriction of the pores due to swelling of the 
PLGA [18]. However, 20 wt% ciprofloxacin MPs displayed a greater initial burst release 
due to an increased amount of adsorbed drug on the surface of the MPs. This occurrence 
could be related to the precipitation of drug during fabrication (Fig. 1). For low molecular 
weight drugs, the bulk of the drug release occurs during days 1–21 with zero-order kinetics 
(Fig. 2). For large molecular weight drugs, release occurs in two bursts between 10 and 38 
days, with the exception of 20 wt% loaded colistin MPs. The biphasic characteristic of drug 
release during this time period is indicative of release due to a combination of diffusion and 
degradation [11]. The PLGA used in this study, PLGA 50:50, degrades through bulk 
erosion, and is an amorphous polymer, leading to faster degradation than other copolymer 
ratios. Upon incubation in PBS pH 7.4, bulk degradation begins via swelling of the PLGA 
and hydrolysis of ester bonds, resulting in decreasing molecular weight and increasing 
polydispersity [40]. After initial immersion in PBS, bulk degradation may result in sufficient 
random chain scission to allow low molecular weight drugs to begin diffusing into the 
surrounding media. In contrast, the higher molecular weight drugs colistin and vancomycin 
cannot begin diffusing out until more significant degradation has occurred after 10 days 
(Fig. 2). This phenomenon could also be influenced by the fact that the larger molecular 
weight drugs in this study also tended to have lower solubility (correlation = −0.88), though 
the correlation of logS to lag phase is relatively weaker than that of molecular weight. The 
length of the lag phase and general release kinetics appear to be mainly influenced by 
molecular weight and solubility, but the rate of release appears to be mainly dependent on 
physical and material properties, such as diffusion and degradation, as supported by the lack 
of correlation between antibiotic properties and release rate (Table 4).
Surprisingly, neither charge nor solubility appears to have a strong effect on the rate of 
antibiotic release from PLGA MPs (Table 4). While colistin demonstrated similar triphasic 
release as vancomycin at 10 wt% loading, colistin appeared to take on the biphasic release 
profile of the small molecular weight drugs at 20 wt% loading. Change in release kinetics 
with increasing concentration of drug has been noted in other studies, possibly as a result of 
Shah et al. Page 10
Pharm Res. Author manuscript; available in PMC 2015 December 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
increased drug content contributing to faster degradation of the polymer and by creation of 
microporosity following drug dissolution [12,41]. It is unclear why this effect was seen with 
colistin and not with vancomycin. The large standard deviation seen in the release of 
cefazolin from 10 wt% loaded MPs was not seen in other formulations, and may indicate 
poor reproducibility in drug distribution within the MPs contributing to differing release 
kinetics.
The cumulative release of many antibiotics in this study did not reach 100% although the 
MPs had fully degraded by the end of the study. This could be due to degradation of the 
antibiotics between time points. Doxycycline is well-known for its photosensitivity and 
degrades in aqueous solution, especially when incubated at 37°C [42]. Although other 
antibiotics undergo some degradation in water, the PLGA matrix may have provided more 
protection from degradation while doxycycline was afforded less protection due to its 
particular sensitivity to light [43–46].
Loss of antibiotic activity is a serious concern when fabricating controlled delivery vehicles. 
Fabrication of PLGA MPs requires the use of an organic solvent and a method of emulsion, 
which may have deleterious effects on antibiotic efficacy. In addition, the MPs are incubated 
in conditions that may cause degradation of some antibiotics, as seen with doxycycline. All 
antibiotics in this study remained effective against susceptible strains at both early and late 
time points (Table 5), ranging from 12 hours to 35 days. The retention of efficacy is likely 
due to protection of the antibiotic within the polymer matrix until it is solubilized and 
released.
Some limitations of this study include the use of only one antibiotic with a negative charge 
and the lack of a standard statistical analysis to complete a main effects analysis on release 
curves. This study could also be expanded to include multiple antibiotics from each class. 
The relation between antibiotic chemistry and release kinetics could be further investigated 
by creating the relatively insoluble freebase counterparts of each antibiotic salt and 
evaluating incorporation into and release from PLGA MPs composed of terminally capped 
and uncapped polymer [37,39,47]. Prior et al. have investigated the relationship between 
gentamicin loading efficiency, end groups of PLGA, and pH of the aqueous phase, finding 
that differences in loading efficiency between capped and uncapped PLGA are likely due to 
a combination of terminal group and pH influence on exposed charges [31]. Further studies 
could elucidate the influence of end-capping on encapsulation by using antibiotics of 
different charges with the same fabrication protocol. While in vitro studies allow for the 
evaluation and comparison of the effects of drug loading on properties and release kinetics 
of PLGA MPs in a well-controlled environment, these results should be further expanded 
upon to evaluate release kinetics in vivo.
The information from this study indicates that consideration of antibiotic charge, molecular 
weight, and solubility is useful in predicting loading efficiency and in vitro release kinetics, 
respectively. This information could be useful in designing PLGA MPs for applications in 
which knowledge of expected release profile is necessary, such as early delivery of a small 
molecule antibiotic to an infected bone defect followed temporally by delivery of a large 
osteogenic protein such as bone morphogenetic protein-2. Furthermore, knowledge of the 
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effect of drug properties can guide choice of polymer and fabrication parameters in order to 
minimize waste during processing and provide a basis for the rational design of PLGA MP 
drug release systems.
5.0 Conclusion
This study analyzed the effects of incorporation of various antibiotics on the properties and 
in vitro release kinetics of degradable, antibiotic-loaded PLGA MPs. Important 
characteristics of the drug-loaded MPs, such as loading efficiency and release kinetics, could 
be explained by the charge and molecular weight of the loaded antibiotic. The charge of 
loaded antibiotic was a significant factor in the loading efficiency, with negative charges 
conferring decreased efficiency compared to positive charges on the antibiotics. The time 
course of antibiotic release was variable between 3 weeks and 7 weeks, and small molecule 
drugs were released more quickly than large molecular weight drugs. Molecular weight also 
determine biphasic or triphasic release pattern, but solubility and partition coefficient did not 
appear to affect the rate of release. Microparticle size was mainly determined by fabrication 
parameters and did not appear to be significantly affected by the loaded drug. Importantly, 
the antibiotics loaded into the MPs retained their efficacy against bacteria both early and late 
in the release. The results of this study indicate that knowledge of the chemical nature of a 
drug can allow for prediction of important properties of drug-loaded MPs, particularly 
loading efficiency and release kinetics.
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Figure 1. 
Representative scanning electron micrographs of whole MPs and cut MPs to demonstrate 
external and internal morphology of cefazolin (a,b,c,d), ciprofloxacin (e,f,g,h), clindamycin 
(i,j,k,l), colistin (m,n,o,p), doxycycline (q,r,s,t), and vancomycin (u,v,w,x) of 10 wt% whole, 
10 wt% cut, 20 wt% whole, and 20 wt% cut MPs, respectively. For comparison, blank MPs 
are shown whole and cut in (y) and (z), respectively. Whole MPs are shown at 100x 
magnification, and cut MPs are shown at 500x magnification. The scale bar represents 100 
μm for rows 1 and 3 and (y), and 50 μm for rows 2 and 4 and (z).
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Figure 2. 
Release curves for a) cefazolin, b) ciprofloxacin, c) clindamycin, d) colistin, e) doxycycline, 
and f) vancomycin loaded PLGA microparticles at 10 wt% and 20 wt%. Significant 
differences between release rates during different phase are indicated by letters. For 
ciprofloxacin loaded MPs, there is a significant different between 10 wt% and 20 wt% 
loaded MPs during Phase 1 (p<0.05). For colistin loaded PLGA MPs, Phase 2 and Phase 3 
are significantly different between 10 wt% and 20 wt% loaded MPs (p<0.05). Ciprofloxacin 
and doxycycline 10 wt% loaded MPs demonstrate increased release of antibiotic during 
Phase 3 compared to 20 wt% loaded MPs, and vancomycin loaded MPs demonstrate 
increased release from 20 wt% MPs compared to 10 wt% MPs in phase 4 (p<0.05). 
Cumulative percent release is the same between 10 wt% and 20 wt% for any antibiotic 
(p>0.05).
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Table II
Loading efficiencies of microparticle formulations.
Loading Efficiency of 10 wt% antibiotic-loaded PLGA 
MPs (%)
Loading Efficiency of 20 wt% antibiotic-loaded PLGA 
MPs (%)
Cefazolin 36.4 ± 3.3a 51.3 ± 6.1d
Ciprofloxacin 86.8 ± 10.9b,c,* 38.9 ± 17.8d,*
Clindamycin 84.9 ± 6.9b,c 89.5 ± 4.0e,f
Colistin 102.0 ± 5.0c 105.3 ± 4.4f
Doxycyline 71.4 ± 2.3b 89.4 ± 0.9e,f
Vancomycin 83.3 ± 4.8b,c 76.9 ± 6.2e
*
Indicates significant difference between 10wt% and 20wt% loaded for a given antibiotic.
Superscript letters indicate significant difference between antibiotics for a given loading wt%
Data is presented as mean ± standard deviation, n=3 per group.
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Table III
Microparticle sizes of each microparticle formulation.
Size of 10 wt% antibiotic-loaded PLGA Microparticles 
(μm)
Size of 20 wt% antibiotic-loaded PLGA Microparticles 
(μm)
Blank 43.34 ± 41.93
Cefazolin 41.9 ± 38.6 47.6 ± 40.3
Ciprofloxacin 60.3 ± 49.7a 36.5 ± 31.9
Clindamycin 48.6 ± 33.4 51.0 ± 40.8
Colistin 41.3 ± 33.3 40.9 ± 34.9
Doxycyline 41.7 ± 33.1 41.5 ± 35.3
Vancomycin 33.1± 28.7b 36.9 ± 28.1
Superscript letters indicate significant difference between groups.
Data is presented as mean ± standard deviation, n=3 per group.
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Table IV
Correlation coefficients between physicochemical properties and loading efficiency, dominant rate of release, 
and length of lag phase.
Charge Molecular Weight logP logS
Loading Efficiency 10 wt% 0.82 0.39 −0.20 −0.13
Loading Efficiency 20 wt% 0.68 0.45 −0.05 −0.34
Release Rate 10 wt% −0.15 −0.14 −0.02 −0.03
Release Rate 20 wt% −0.26 −0.19 −0.47 −0.18
Length of Lag Phase 10 wt% 0.64 0.85 −0.57 −0.75
Length of Lag Phase 20 wt% 0.55 0.93 −0.68 −0.86
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